Actively Recruiting

Phase 4
Age: 20Years - 99Years
All Genders
NCT04913870

Angiotensin Receptor Blockers in Aortic Stenosis

Led by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Updated on 2024-12-20

144

Participants Needed

2

Research Sites

365 weeks

Total Duration

On this page

Sponsors

I

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Lead Sponsor

O

Odense University Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.

CONDITIONS

Official Title

Angiotensin Receptor Blockers in Aortic Stenosis

Who Can Participate

Age: 20Years - 99Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Mild to moderate aortic stenosis defined by peak aortic jet velocity between 2.5 and less than 4 m/s
  • Normal left ventricular ejection fraction of 50% or higher
  • Systolic blood pressure greater than 110 mmHg
  • Diastolic blood pressure greater than 70 mmHg
Not Eligible

You will not qualify if you...

  • More than mild aortic or mitral valve regurgitation or presence of mitral stenosis
  • Current use or medical indication for renin-angiotensin system medications or Aliskiren
  • Known allergy or intolerance to angiotensin II receptor blockers (ARBs)
  • Diagnosis of Alzheimer’s disease, dementia, or known non-compliance with treatments
  • Renal dysfunction with glomerular filtration rate below 30 ml/min/1.73m2
  • Chronic high potassium levels (hyperkalemia)
  • Diagnosed liver failure, cirrhosis, hepatitis, or history of liver impairment
  • Newly diagnosed diabetes within the past 2 months or poorly controlled diabetes
  • Existing obstructive coronary artery disease with severe angina or recent heart attack within 3 months
  • Pregnant or breastfeeding women
  • Inability to read, understand, or sign the research consent form

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

CRIUCPQ

Québec, Quebec, Canada, G1V 4G5

Actively Recruiting

2

Odense University Hospital

Odense, Denmark

Actively Recruiting

Loading map...

Research Team

M

Marie-Annick Clavel, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here